Extracellular matrix stiffness and mechanotransduction in cancer drug resistance
Drug Resistance Updates · 2026
DOI: 10.1016/j.drup.2026.101470 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Yang Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang 110004, China. Hauptthemen laut MEDLINE: Extracellular Matrix, Mechanotransduction, Cellular, Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 312 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Extracellular matrix (ECM) is a key component in the tumor microenvironment (TME). The stiffened ECM not only acts as a barrier to prevent drug delivery but also facilitates tumor progression via activating cell membrane receptors and mechanical sensors, such as Piezo1 ion channels, integrins, and Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ). Accumulating evidence suggests that stiffer ECM and aberrant mechanotransduction contribute to treatment resistance. Targeting ECM stiffness and mechanotransduction pathways and restoring mechanical abnormalities in the TME provide opportunities for the rational design of combination therapies, especially in drug-resistant tumors. Therefore, elucidating how ECM stiffness regulates cancer drug resistance will facilitate the development of new therapeutic strategies for improving patient outcomes. In this review, we summarize the key factors that regulate ECM stiffness during tumor progression. We comprehensively analyze the multi-faceted mechanisms of ECM stiffness in cancer therapy resistance and discuss potential strategies that target ECM components and downstream signaling pathways for improving treatment efficacy. This comprehensive review will enhance the understanding of the functional roles of ECM stiffness and mechanotransduction in cancer drug resistance, providing basic knowledge for exploring novel therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynaecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang 110004, China.
- Department of Health Management, Shengjing Hospital of China Medical University, Shenyang 110004, China.
- Department of Geriatrics, The First Hospital of China Medical University, Shenyang 110001, China.
- Department of Oncology, University of Cambridge, Cambridge CB2 0AH, UK.
- Department of Gynaecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang 110004, China; Department of Pathophysiology, College of Basic Medical Sciences, China Medical University, Shenyang 1101…
- Department of Urology, The Third Affiliated Hospital of Shenyang Medical College (Shenyang 242 Hospital), Shenyang 110034, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Song, Y., Huang, C., Han, J., Wang, S., Liu, H., Li, Y., Jiang, Z., Tan, X., Wu, T., & Jiang, F. (2026). Extracellular matrix stiffness and mechanotransduction in cancer drug resistance. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101470
Vancouver
Song Y, Huang C, Han J, Wang S, Liu H, Li Y, et al. Extracellular matrix stiffness and mechanotransduction in cancer drug resistance. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101470
BibTeX
@article{Song2026,
author = {Song, Yang and Huang, Chenglin and Han, Jinyu and Wang, Shizhuo and Liu, Hengrui and Li, Yang and Jiang, Zhongwei and Tan, Xiaolin and Wu, Tianyi and Jiang, Fengli},
title = {Extracellular matrix stiffness and mechanotransduction in cancer drug resistance},
journal = {Drug Resistance Updates},
year = {2026},
doi = {10.1016/j.drup.2026.101470}
}
EUVIMED